Best Immunotherapy Companies in New York City, United States
The 48 best Immunotherapy companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunovant.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in New York City
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 19 mo ago | Public | — | 2016 | Apple iCloud MailBootstrapAmazon Web Services+20 | — | — |
| 2 | IRX Therapeutics Developing innovative cell therapies for advanced cancer and autoimmune diseases | $190M | 107 mo ago | Acqui-Hired | — | 1994 | — | — | — |
| 3 | Caladrius Biosciences Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer and limbic… | $128M | 66 mo ago | Public | — | 1980 | — | — | — |
| 4 | Elevation Oncology Developer of precision medicine for the treatment of cancer | $98M | 68 mo ago | Public | Shawn Leland Founder | 2019 | WordPress Block EditorWordPressMySQL+27 | 5 patents Therapeutic anti‑ERBB3 (HER3) monoclonal antibodies for NRG1‑fusion driven cancers | — |
| 5 | Mustang Bio Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment | $95M | 33 mo ago | Public | Manuel Litchman CEO | 2015 | WordPressPleskMySQL+19 | — | — |
| 6 | Y-mAbs Therapeutics Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens. | $90M | 104 mo ago | Acquired | — | 2014 | DrupalPHPBootstrap+24 | — | — |
| 7 | Promontory Therapeutics Developer of immunotherapeutics for the treatment of cancer | $72M | 56 mo ago | Series A | Matthew Price Co-Founder & COO | 2010 | — | — | — |
| 8 | Checkpoint Therapeutics Developer of immunotherapy and targeted cancer treatments to improve healthcare access | $58M | 127 mo ago | Acquired | — | 2014 | BootstrapApache HTTP ServerjQuery+7 | — | — |
| 9 | Fortress Biotech Developing novel immunotherapy agents for cancer and inflammatory diseases | $55M | 101 mo ago | Public | Lindsay Rosenwald CEO | 2006 | BootstrapApache HTTP ServerMatomo Analytics+15 | — | — |
| 10 | Panacela Labs Development and commercialization of drugs for the treatment of oncology or other diseases. | $40M | 127 mo ago | Deadpooled | Yakov Kogan CEO | 2011 | — | 32 patents Immuno‑oncology therapeutics: TLR agonist gene vectors and Myc‑targeting small molecules. | — |
| 11 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 7 mo ago | Public | William Ho Founder & CEO | 2020 | DrupalPHPZURB Foundation+22 | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies and targeted peptide cancer treatments | — |
| 12 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 23 mo ago | Series A | David Ho Co-Founder | 2016 | — | 11 patents Patents concentrated in health & consumer products | — |
| 13 | TG Therapeutics Developer of treatments for B-cell malignancies and autoimmune diseases | $25M | 173 mo ago | Public | — | 1993 | WordPressPleskMySQL+25 | 1,872 patents Patents concentrated in chemistry & materials | — |
| 14 | Actinium Pharma Developer of radiation conjugates antibodies for the treatment of cancer | $18M | 71 mo ago | Public | — | 2000 | BootstrapApache HTTP ServerAmazon Web Services+9 | — | — |
| 15 | Adjuvance Technologies Involved in vaccine adjuvant design and manufacturing. | $13M | 74 mo ago | Series A | — | 2009 | — | 15 patents Vaccine adjuvant development using triterpene saponin synthesis and analogues | — |
| 16 | Caelum Biosciences Chimeric fibril-reactive monoclonal antibody (mAb) for the treatment of AL Amyloidosis | $10M | 106 mo ago | Acqui-Hired | Michael Spector Co-Founder & CEO | 2017 | — | — | — |
| 17 | PIN Pharma US-based, preclinical-stage biopharma, developing a broad-base immunomodulatory cancer therapy | $7M | — | Series A | — | 2011 | — | — | — |
| 18 | Aethon Therapeutics Developer of immunotherapies for cancer treatment | $6M | 22 mo ago | Series A | Benjamin Neel Co-Founder | 2022 | — | — | — |
| 19 | Helocyte Developing immunotherapies for cancer and infectious diseases, particularly cytomegalovirus | $4M | 117 mo ago | Funding Raised | — | 2015 | — | — | — |
| 20 | Immune Pharmaceuticals Developer of therapeutic agents for the treatment of immunologic and inflammatory diseases | $4M | 104 mo ago | Public | — | 1993 | — | — | — |
| 21 | Intrommune Developing oral mucosal immunotherapy toothpaste for food allergy management | $3M | 32 mo ago | Series A | Michael Nelson Founder & CEO | 2015 | — | — | — |
| 22 | AV Therapeutics Specialty company developing cancer therapeutics and immunotherapeutic vaccines | $2M | 146 mo ago | Deadpooled | Abe Mittleman CEO | 2007 | — | 1,872 patents Patents concentrated in chemistry & materials | — |
| 23 | Akari Therapeutics Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. | $2M | 7 mo ago | Public | Ray Prudo Chairman | 2005 | WordPressMySQLPHP+16 | — | — |
| 24 | Cynvec Developing innovative viral immunotherapies, pioneering cancer treatment using the body's immune system | $2M | 73 mo ago | Seed | Daniel Wilds ex-Acting President and CEO | 2004 | — | — | — |
| 25 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 205 mo ago | Funding Raised | Peter Blackburn President and Founder | 2004 | — | — | — |
| 26 | Synthis Therapeutics Developer of therapeutics to treat cancer | $1M | 22 mo ago | Funding Raised | Dori Karyat Founder & CEO | 2017 | — | — | — |
| 27 | PyrOjas Developer of autologous whole-cell vaccine for durable cancer control | $748K | 22 mo ago | Funding Raised | Archis B Founder & CEO | 2021 | — | 3 patents Immunotherapy pharmaceutical compositions for cancer treatment | — |
| 28 | Nomocan Pharmaceuticals Developing first-in-class targeted monoclonal antibody therapies for aggressive cancers | $740K | 138 mo ago | Seed | Ehsan Yazdi Founder & CEO | 2014 | — | — | — |
| 29 | Manhattan BioSolutions Developer of immunotherapies for treating cancer | $546K | 71 mo ago | Funding Raised | Borys Shor Co-Founder & CEO | 2016 | — | — | — |
| 30 | MiNK Therapeutics Developer of T cell therapies for cancer and other immune-mediated diseases | $306K | 15 mo ago | Public | Jennifer Buell CEO | 2017 | DrupalPHPBootstrap+25 | — | — |
| 31 | Ichor Biologics Developer of monoclonal antibodies for treating infectious and inflammatory diseases | $300K | 87 mo ago | Funding Raised | Raymond Alvarez Co-Founder & CEO | 2015 | — | 6 patents Therapeutic and diagnostic antibodies targeting Andes hantavirus | — |
| 32 | Hepione Therapeutics Developer of immuno-therapeutics for opioid overdose and cancer | $262K | 70 mo ago | Funding Raised | Joey Verdi Co-Founder | 2019 | — | — | — |
| 33 | Humane Genomics Developer of cancer therapeutics using the oncolytic virus | $125K | 17 mo ago | Seed | Chad Moles Co-Founder & CSO | 2016 | — | 10 patents Engineered oncolytic viruses and modular viral genome platforms for targeted cancer therapy | — |
| 34 | Brooklyn ImmunoTherapeutics Developer of cytokine-based therapeutics for treating cancer | — | 53 mo ago | Late Stage | Mark Leuchtenberger CEO & President | 2018 | — | 11 patents Combination checkpoint inhibitor and multi‑cytokine biologic therapies for cancer immunotherapy | 1 launch |
| 35 | BeyondSpring Pharma Innovative biopharmaceutical company focused on cancer therapies and targeted protein degradation | — | 106 mo ago | Public | — | 2013 | WordPressMySQLMariaDB+22 | — | — |
Top 12 Immunotherapy companies in New York City
#1
Public · New York City, New York · founded 2020 · 31 employees$35Mraised▾
Provider of immune based therapies for the treatment of cancer. The company offers its proprietary technology and develop genetically modified gamma-delta (γδ) T cells for targeting cold, low mutation cancers cell. It offers pipeline of drug candidates which include INB-200 for glioblastoma, INB-100 for leukemia, INB-400 for solid tumors, and others.
- Dec 2025Post IPO$20.1M
- Oct 2024Post IPO$12.4M
- Dec 2023Post IPO$14.4M
- Sep 2020Series C$35M
#2
Public · New York City, New York · founded 2016 · 1 employees$685Mraised▾
Provider of therapeutic solutions to treating autoimmune diseases. The company's product line include, IMVT-1401, is a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient needs and a range of autoimmune diseases. The candidate is meant for diseases like Myasthenia Gravis, and Graves’ Ophthalmopathy.
- Jan 2025Post IPO$450M
- Jan 2022Post IPO—
- Aug 2021Post IPO$200M
- Oct 2019Conventional Debt$35M
#3
Public · New York City, New York · founded 2005 · 5 employees$2.4Mraised▾
Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. Its lead candidate is Nomacopan is being evaluated for four therapeutic areas which include bullous pemphigoid (BP), a severe blistering skin disease, thrombotic microangiopathy, AMD, and asthma. It is also developed compounds that inhibit the leukotriene system such as thromboxane A2.
- Dec 2025Post IPO—
- Mar 2025Post IPO$7.6M
- Dec 2023Post IPO—
- Jul 2021Post IPO$12.3M
#4
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
#5
Public · New York City, New York · founded 2015 · 80 employees$95Mraised▾
Mustang Bio is a developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment. Its drug pipeline includes engineered Chimeric Antigen Receptor & T-cells (CAR-T) targeting interleukin 13 Receptor α2 which is overexpressed on the surface of glioblastoma (GBM) cells (Phase 1); and CAR-T targeting CD123, which is overexpressed on the surface of Acute Myeloid Leukemia (AML) cells (Phase 1). The company also has sponsored a preclinical research agreement in place with COH to develop additional CAR-T cell products.
- Oct 2023Post IPO$4.7M
- Sep 2021Grant (prize money)$2M
- Aug 2019Grant (prize money)$9.3M
- Apr 2019Conventional Debt$15M
#6
Series A · New York City, New York · founded 2022 · 7 employees$6Mraised▾
Developer of immunotherapies for cancer treatment. It offers antibodies in combination with targeted covalent inhibitors of RAS, EGFR, and other cancer-associated mutations to selectively kill drug-resistant cancer cells. It is based on HapImmune platform that activate T cells that will kill tumor cells.
- Sep 2024Grant (prize money)$499.9K
- Apr 2023Grant (prize money)$499.5K
- Dec 2022Series A$6M
#7
Funding Raised · New York City, New York · founded 2017 · 3 employees$1.4Mraised▾
Synthis Therapeutics is developing therapeutics to treat cancer by stimulating the immune system. The company is developing therapeutics that inhibit the immunosuppressive pathways such as TGF-β pathway to treat cancer.
- Sep 2024Grant (prize money)$579K
- Jun 2023Grant (prize money)$299.9K
- Aug 2019Grant (prize money)$510K
#8
Public · New York City, New York · founded 2017 · 37 employees$306.5Kraised▾
Developer of T cell therapies for cancer and other immune-mediated diseases. The company has engineered iNKT cell therapies and bispecific iNKT cell engages for the treatment of solid tumors, multiple myeloma, GvHD, and others.
- May 2025Grant (prize money)$306.5K
#9
Public · New York City, New York · founded 1980 · 53 employees$128.3Mraised▾
Developer of cell therapy-based drugs for coronary microvascular dysfunction, diabetes, cancer, and limbic ischemia. The company has developed 3 immune-modulating technologies namely - T Regulatory Cell Technology (which infuses polyclonal antibodies to restore the immune balance that is distorted in most cases of autologous and allergic diseases), Tumor Cell / Dendritic Cell Technology (which involves the use of Cancer-Initiating Cells and dendritic cells to mount an immune response) and a CD34 Cell Technology (that involves the transfer of CD34 cells in the bone marrow and peripheral blood for ischemic repair). Its pipeline has cell therapies for type 1 diabetes based on T-regulatory (Treg) cell-based therapy and limbic ischemia (based on CD34 cell technology). The company partners with others to co-develop therapies based on its technologies and also has a subsidiary called PCT, a cell therapy CDMO. Caladrius, in partnership with Invetech, is also developing a closed processing system to increase the level of automation in cell manufacturing processes.
- Jan 2021Post IPO$25M
- Jan 2017Post IPO$6M
- Sep 2016Post IPO$12.6M
- Mar 2016Post IPO$1M
#10
Funding Raised · New York City, New York · founded 2021$748.3Kraised▾
Developer of autologous whole-cell vaccine for durable cancer control. The company engineers immune therapies to reprogram the body to remember cancer. Its lead platform, PyroCells, is a whole-cell vaccine engineered from the patient's own tumor to activate a broad T cell response against diverse antigens. The vaccine uses the patient’s entire tumor as the immunogen, activating a diversified immune response that recognizes heterogeneous cancer antigens. It combines potent adjuvants with non-viral engineering efficiency. The company also licenses PyroTIMER, a plug-in to boost T cell function in solid tumors.
- Sep 2024Grant (prize money)$748.3K
#11
Acqui-Hired · New York City, New York · founded 1994 · 29 employees$190.4Mraised▾
Developing innovative cell therapies for advanced cancer and autoimmune diseases. This therapeutics company engineers induced pluripotent stem cells (iPSCs) and differentiates them into mesenchymal stem cells (iMSCs). Their allogeneic synthetic iMSCs offer a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting. The lead cell therapy treatment targets ovarian cancer, addressing the lack of effective targeted therapies and high recurrence rates. Another cell therapy product is designed to target inflammation and treat autoimmune diseases, offering a next-generation anti-inflammatory therapy. This approach leverages the natural tumor-homing abilities of MSCs to deliver therapeutic cytokines directly to the tumor microenvironment, triggering a strong immune response. The company is focused on transforming treatments and delivering hope through precision-guided therapeutics.
- Aug 2017Series C$33.2M
- Jan 2017Series C$13.2M
- Nov 2016Series C$6.4M
- May 2016Series B$2M
#12
Series A · New York City, New York · founded 2010 · 17 employees$72.3Mraised▾
Developer of immunotherapeutics for the treatment of cancer. The company's lead agent, PT-112, is an immunogenic cell death (ICD) inducer to treat solid tumors, hematological cancers, and more.
- Dec 2021Series A$37.3M
- Aug 2020Series A$18.4M
- Oct 2018Series A$16.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.